Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

OnabotulinumtoxinA for Treatment of Chronic Migraine: 56-Week Analysis of the PREEMPT Chronic Migraine Subgroup with Baseline Acute Headache Medication Overuse
Headache
(-)
005
Authors/Disclosures
Stephen D. Silberstein, MD, FÂé¶¹´«Ã½Ó³»­ Dr. Silberstein has received publishing royalties from a publication relating to health care.
Joel R. Saper, MD, FÂé¶¹´«Ã½Ó³»­ (MHNI) No disclosure on file
Michael R. Stein, MD No disclosure on file
No disclosure on file
Catherine C. Turkel, Pharm (Allergan, Inc.) No disclosure on file
Pauline Maki, PhD (University of Illinois) Dr. Maki has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Astellas. Dr. Maki has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bayer. Dr. Maki has or had stock in Estrigenix. The institution of Dr. Maki has received research support from National Institute of Health. The institution of Dr. Maki has received research support from Wellcome Leap. The institution of Dr. Maki has received research support from The Advanced Research Projects Agency. Dr. Maki has received personal compensation in the range of $0-$499 for serving as a Study Section Reviewer with NIH. Dr. Maki has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Boston Consulting. Dr. Maki has received personal compensation in the range of $500-$4,999 for serving as a Speaker with InflectionIQ.
No disclosure on file